Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
BiologicsMolecular Targeted Therapeutics

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1737517

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1737517

Antibody Discovery

PUBLISHED:
PAGES: 224 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Antibody Discovery Market to Reach US$3.3 Billion by 2030

The global market for Antibody Discovery estimated at US$1.9 Billion in the year 2024, is expected to reach US$3.3 Billion by 2030, growing at a CAGR of 9.8% over the analysis period 2024-2030. Monoclonal Antibody, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Polyclonal Antibody segment is estimated at 10.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$500.0 Million While China is Forecast to Grow at 9.5% CAGR

The Antibody Discovery market in the U.S. is estimated at US$500.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$530.7 Million by the year 2030 trailing a CAGR of 9.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.9% and 8.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.9% CAGR.

Global Antibody Discovery Market - Key Trends & Drivers Summarized

Why Is Antibody Discovery at the Forefront of Next-Generation Therapeutic Development?

Antibody discovery is emerging as a cornerstone of modern drug development, driven by the escalating demand for targeted therapies across oncology, autoimmune disorders, infectious diseases, and rare conditions. Monoclonal antibodies (mAbs), bispecific antibodies, and antibody-drug conjugates (ADCs) are transforming clinical outcomes through their high specificity, tunable pharmacokinetics, and ability to engage or inhibit precise molecular targets. The discovery phase-encompassing target identification, antibody generation, screening, and lead optimization-is critical to ensuring downstream therapeutic efficacy, safety, and commercial viability. As biopharmaceutical pipelines increasingly prioritize biologics over small molecules, antibody discovery is becoming an indispensable gateway to innovation.

A significant driver of this trend is the surge in demand for personalized medicine and immunotherapy, where antibody-based therapeutics are used to modulate immune response, block disease-associated pathways, or deliver cytotoxic payloads directly to tumor cells. The urgency created by the COVID-19 pandemic further underscored the importance of rapid antibody discovery, as neutralizing antibodies became pivotal in the therapeutic and diagnostic response to SARS-CoV-2. Global interest in therapeutic antibodies is prompting pharmaceutical and biotech firms to accelerate discovery programs using faster, more predictive, and less immunogenic methods. As the market shifts from traditional hybridoma techniques to humanized platforms and next-gen in silico approaches, antibody discovery is positioned at the heart of biopharma R&D strategies worldwide.

How Are Technological Innovations Accelerating Discovery Timelines and Improving Lead Quality?

Cutting-edge technologies are reshaping every stage of the antibody discovery process, enabling faster identification of high-affinity, developable antibodies with favorable safety and manufacturability profiles. Phage display and yeast display platforms have largely replaced traditional hybridoma-based generation, offering vast diversity libraries and rapid selection capabilities. More recently, microfluidics, single B-cell screening, and high-throughput sequencing have revolutionized early-stage discovery by capturing naturally occurring antibody repertoires from immunized animals or convalescent human donors. These tools enable the isolation of rare, highly potent antibodies that would otherwise go undetected through conventional methods.

Computational biology and AI-driven design are also transforming the discovery pipeline by predicting binding affinity, stability, immunogenicity, and epitope specificity in silico. Machine learning algorithms are being trained on large antibody datasets to accelerate lead optimization, reduce experimental trial-and-error, and improve success rates in later development phases. Humanization techniques-ranging from chimerization to full deimmunization-are being refined to enhance safety and reduce rejection risk. Additionally, CRISPR/Cas9 and transgenic animal models are being leveraged to generate fully human antibodies with precise specificity. These technology integrations are enabling rapid, scalable, and cost-efficient antibody discovery workflows that meet the high standards of regulatory and therapeutic rigor.

Where Is Market Demand Rising and Which Therapeutic Areas Are Driving Discovery Investment?

Market demand for antibody discovery services and platforms is rising sharply across North America, Europe, and Asia-Pacific, where biopharma companies, academic labs, and contract research organizations (CROs) are intensifying efforts to expand antibody-based pipelines. The U.S. leads in therapeutic antibody development, backed by significant biotech investment, advanced research infrastructure, and regulatory support for expedited biologic approvals. Europe, particularly Germany, Switzerland, and the U.K., is seeing strong growth in CRO-based discovery partnerships and academic spinouts. Meanwhile, Asia-Pacific-especially China, South Korea, and Japan-is becoming a major hub for antibody innovation, fueled by state-backed biotech programs, growing clinical trial activity, and rapid commercialization strategies.

Oncology remains the largest and fastest-growing therapeutic segment for antibody discovery, accounting for the majority of pipeline activity in monoclonal and bispecific antibodies. Immuno-oncology applications, such as checkpoint inhibitors and T-cell engagers, are expanding rapidly with significant investment in PD-1/PD-L1, CTLA-4, CD3, and CD20 targets. Autoimmune and inflammatory diseases-including rheumatoid arthritis, psoriasis, and Crohn’s disease-also represent major discovery areas, with antibody candidates aimed at cytokines and immune receptors such as IL-6, TNF-alpha, and IL-17. Infectious disease research continues to drive antibody discovery in the wake of COVID-19, with new programs targeting HIV, RSV, and influenza. Rare and neurological diseases, including ALS, Alzheimer’s, and neuromyelitis optica, are emerging as high-value niches for precision antibody therapies. These diverse and expanding indications are propelling sustained investment and innovation in antibody discovery workflows across sectors.

What Is Fueling the Growth of the Global Antibody Discovery Market?

The growth in the antibody discovery market is driven by several factors, including the rising prevalence of chronic and rare diseases, expansion of biologics pipelines, and breakthroughs in molecular screening and AI-assisted drug design. A central driver is the therapeutic success of antibodies already in the market-such as trastuzumab, adalimumab, and pembrolizumab-which continue to demonstrate the clinical and commercial potential of antibody-based drugs. The robust deal activity between pharmaceutical giants and antibody discovery specialists is further catalyzing growth, as companies seek early access to differentiated platforms and promising candidates.

Increased outsourcing by biotech startups and mid-sized firms is also fueling market demand for discovery-as-a-service models, where CROs and specialized technology vendors provide end-to-end discovery capabilities from antigen design to humanized lead delivery. Advances in automation, sequencing, and data analytics are lowering the cost per discovery while improving success predictability, making antibody R&D more accessible to smaller players. Moreover, government and institutional funding for pandemic preparedness, cancer immunotherapy, and biosimilar development are boosting both public and private sector involvement. As antibody therapeutics become increasingly central to precision medicine and immune modulation, a crucial question emerges: Can antibody discovery platforms keep pace with the clinical complexity and specificity required for next-generation, globally accessible biologic treatments?

SCOPE OF STUDY:

The report analyzes the Antibody Discovery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Antibody Type (Monoclonal, Polyclonal, Other Antibody Types); Service (Phage Display, Hybridoma, Other Services); End-Use (Pharmaceutical & Biotechnology Companies, Research Laboratories, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

  • Abcam plc
  • AbCellera Biologics Inc.
  • Ablexis, LLC
  • Adimab LLC
  • Akeso Biopharma
  • Biocytogen Pharmaceuticals Co., Ltd.
  • Bruker Corporation
  • Charles River Laboratories
  • ChemPartner
  • Creative Biolabs
  • Danaher Corporation
  • Eurofins Scientific
  • Evotec SE
  • FairJourney Biologics S.A.
  • Genmab A/S
  • GenScript Biotech Corporation
  • Harbour BioMed
  • Icosagen AS
  • ImmunoPrecise Antibodies Ltd.
  • Isogenica Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

Show more
Product Code: MCP33449

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Antibody Discovery - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Demand for Precision Biologics Spurs Innovation Across the Antibody Discovery Landscape
    • AI-Driven Screening Platforms Shorten Discovery Timelines for Therapeutic Antibodies
    • Next-Generation Sequencing and Single-Cell Tools Redefine Antibody Target Identification
    • CRO Partnerships Accelerate Outsourced Antibody Discovery Among Biopharma Firms
    • Oncology and Autoimmune Therapies Dominate the Clinical Focus of Antibody Discovery Pipelines
    • Transgenic Animal Models Expand the Scope of Novel Antibody Generation
    • Bispecific and Monoclonal Advances Unlock Complex Disease Targeting in Antibody Discovery
    • Data Integration Across Platforms Enhances Efficiency in Antibody Optimization
    • Collaborations with Academia Infuse Innovation into Antibody Discovery Frameworks
    • Expiry of Biologic Patents Opens New Pathways for Biosimilar Antibody Development
    • Regulatory Support for First-in-Class Biologics Encourages Bold Innovation in Discovery
    • End-to-End Platform Integration Strengthens the Commercial Value Chain in Antibody Discovery
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Antibody Discovery Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Antibody Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Antibody Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Antibody Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Monoclonal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Monoclonal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Monoclonal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Polyclonal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Polyclonal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Polyclonal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Antibody Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Antibody Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Antibody Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Phage Display by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Phage Display by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Phage Display by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hybridoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hybridoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hybridoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Pharmaceutical & Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Pharmaceutical & Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Pharmaceutical & Biotechnology Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Research Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Research Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Research Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Antibody Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Antibody Discovery by Antibody Type - Percentage Breakdown of Value Sales for Monoclonal, Polyclonal and Other Antibody Types for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Antibody Discovery by Service - Percentage Breakdown of Value Sales for Phage Display, Hybridoma and Other Services for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Antibody Discovery by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Antibody Discovery by Antibody Type - Percentage Breakdown of Value Sales for Monoclonal, Polyclonal and Other Antibody Types for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Antibody Discovery by Service - Percentage Breakdown of Value Sales for Phage Display, Hybridoma and Other Services for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Antibody Discovery by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Antibody Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Antibody Discovery by Antibody Type - Percentage Breakdown of Value Sales for Monoclonal, Polyclonal and Other Antibody Types for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Antibody Discovery by Service - Percentage Breakdown of Value Sales for Phage Display, Hybridoma and Other Services for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Antibody Discovery by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Antibody Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Antibody Discovery by Antibody Type - Percentage Breakdown of Value Sales for Monoclonal, Polyclonal and Other Antibody Types for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Antibody Discovery by Service - Percentage Breakdown of Value Sales for Phage Display, Hybridoma and Other Services for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Antibody Discovery by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Antibody Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Antibody Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Antibody Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Antibody Discovery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Antibody Discovery by Antibody Type - Percentage Breakdown of Value Sales for Monoclonal, Polyclonal and Other Antibody Types for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Antibody Discovery by Service - Percentage Breakdown of Value Sales for Phage Display, Hybridoma and Other Services for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Antibody Discovery by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Antibody Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Antibody Discovery by Antibody Type - Percentage Breakdown of Value Sales for Monoclonal, Polyclonal and Other Antibody Types for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Antibody Discovery by Service - Percentage Breakdown of Value Sales for Phage Display, Hybridoma and Other Services for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Antibody Discovery by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Antibody Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Antibody Discovery by Antibody Type - Percentage Breakdown of Value Sales for Monoclonal, Polyclonal and Other Antibody Types for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Antibody Discovery by Service - Percentage Breakdown of Value Sales for Phage Display, Hybridoma and Other Services for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Antibody Discovery by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Antibody Discovery by Antibody Type - Percentage Breakdown of Value Sales for Monoclonal, Polyclonal and Other Antibody Types for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Antibody Discovery by Service - Percentage Breakdown of Value Sales for Phage Display, Hybridoma and Other Services for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Antibody Discovery by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Antibody Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Antibody Discovery by Antibody Type - Percentage Breakdown of Value Sales for Monoclonal, Polyclonal and Other Antibody Types for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Antibody Discovery by Service - Percentage Breakdown of Value Sales for Phage Display, Hybridoma and Other Services for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Antibody Discovery by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Rest of Europe 15-Year Perspective for Antibody Discovery by Antibody Type - Percentage Breakdown of Value Sales for Monoclonal, Polyclonal and Other Antibody Types for the Years 2015, 2025 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Rest of Europe 15-Year Perspective for Antibody Discovery by Service - Percentage Breakdown of Value Sales for Phage Display, Hybridoma and Other Services for the Years 2015, 2025 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Europe 15-Year Perspective for Antibody Discovery by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Antibody Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Asia-Pacific 15-Year Perspective for Antibody Discovery by Antibody Type - Percentage Breakdown of Value Sales for Monoclonal, Polyclonal and Other Antibody Types for the Years 2015, 2025 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Asia-Pacific 15-Year Perspective for Antibody Discovery by Service - Percentage Breakdown of Value Sales for Phage Display, Hybridoma and Other Services for the Years 2015, 2025 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Asia-Pacific 15-Year Perspective for Antibody Discovery by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of World 15-Year Perspective for Antibody Discovery by Antibody Type - Percentage Breakdown of Value Sales for Monoclonal, Polyclonal and Other Antibody Types for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of World 15-Year Perspective for Antibody Discovery by Service - Percentage Breakdown of Value Sales for Phage Display, Hybridoma and Other Services for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of World 15-Year Perspective for Antibody Discovery by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!